Effects of Intraoperative Low-Dose Esketamine on Postoperative Inflammatory Response and Clinical Recovery in Elderly Patients Undergoing Colorectal Cancer Resection: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
<title>Abstract</title> <p> Surgical trauma in elderly patients undergoing colorectal cancer resection often triggers a robust systemic inflammatory response leading to delayed recovery. Esketamine, a noncompetitive NMDA receptor antagonist, may possess anti-inflammatory properties. This study aimed to evaluate the effects of intraoperative low-dose esketamine on serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) levels, and clinical recovery outcomes in this population. <bold/> This was a single-center, prospective, randomized, double-blind, placebo-controlled trial. Sixty elderly patients (60–85 years, ASA grade I–II) scheduled for elective laparoscopic radical resection of colorectal cancer were randomized (1:1) to receive either low-dose esketamine (0.2 mg/kg/h) or normal saline (control) during anesthesia maintenance. The primary outcome was the concentration of serum TNF-α at preoperative, 0.5h, and 16h postoperative time points. Secondary outcomes included IL-6 levels, intraoperative propofol consumption, anesthesia recovery and extubation times, postoperative Visual Analogue Scale scores, the frequency of patient-controlled analgesia compressions, and the incidence of adverse events. Forty-six patients (n=26 in the esketamine group; n=20 in the control group) were finally included in the statistical analysis. Compared to the control group, the esketamine group exhibited significantly lower TNF-α concentrations at 0.5h and 16h postoperatively (P < 0.05). After adjusting for baseline imbalance, no statistically significant differences were observed in postoperative IL-6 levels between the two groups (P > 0.05). The esketamine group showed significantly lower intraoperative propofol consumption (P < 0.001), shorter anesthesia recovery and extubation times (P < 0.05), and reduced VAS scores at 6h-48h post-surgery (P < 0.05). Furthermore, hospitalization duration was shorter in the esketamine group (P < 0.001). There was no significant increase in adverse events such as hallucinations or nausea. <bold/> Intraoperative low-dose esketamine (0.2 mg/kg/h) effectively suppresses the postoperative release of TNF-α, reduces propofol requirements, and enhances postoperative analgesia and clinical recovery in elderly patients undergoing colorectal surgery. <bold>Trial Registration:</bold> The study was retrospectively registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2500101206) on April 22, 2025. </p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.